Table 3.
Percentage of Women With an HPV16 Genotype Result at Previous Cytology,a Stratified by Laboratory L vs All Other Laboratories
| Laboratory L
|
Other Laboratories
|
P Value | |||||
|---|---|---|---|---|---|---|---|
| n | Col %b | % HPV16+ | n | Col %b | % HPV16+ | ||
| Total | 2,756 | 100.0 | 23.6 | 2,829 | 100.0 | 24.0 | .691 |
| Biopsy specimen result | |||||||
| Normal | 1,332 | 48.3 | 16.7 | 874 | 30.9 | 14.2 | .107 |
| CIN1 | 761 | 27.6 | 17.0 | 1,525 | 53.9 | 19.6 | .125 |
| CIN2 | 421 | 15.3 | 39.0 | 197 | 7.0 | 57.4 | <.001 |
| CIN2–3 | 70 | 2.5 | 50.0 | 112 | 4.0 | 63.4 | .075 |
| CIN3 | 149 | 5.4 | 59.7 | 113 | 4.0 | 61.1 | .827 |
| Carcinoma | 23 | 0.8 | 39.1 | 8 | 0.3 | 37.5 | 1.000 |
CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus.
a
Cytology taken within 1 year of biopsy specimen reading.
b
Column percentages (Col %) are not representative of the laboratory distribution because a stratified sample of specimens was selected. Biopsy specimen results between laboratory L and other laboratories were statistically different, P < .001.